WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 4 fonti

'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

Raccontata datheguardian.combbc.comindependent.co.ukinews.co.uk

Confronto fonti

4 prospettive sulla stessa storia
AI · summaries
bbc.comStai leggendo2 mesi fa

'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

originale
inews.co.uk2 mesi fa

These new Alzheimer's drugs could transform treatment

Two 'breakthrough' medicines have no worthwhile benefits, scientists say - so where do hopes really lie?

Leggi questa versione → originale
theguardian.com2 mesi fa

Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline

Leggi questa versione → originale
independent.co.uk2 mesi fa

Alzheimer’s drugs ‘make no meaningful difference to patients’, major study claims

Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 16 aprile 2026·theguardian.com

    Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

    Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline

  2. giovedì 16 aprile 2026·bbc.com

    'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests

    A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

  3. giovedì 16 aprile 2026·independent.co.uk

    Alzheimer’s drugs ‘make no meaningful difference to patients’, major study claims

    Two anti-amyloid drugs – lecanemab and donanemab – are licensed for use in the UK

  4. giovedì 16 aprile 2026·inews.co.uk

    These new Alzheimer's drugs could transform treatment

    Two 'breakthrough' medicines have no worthwhile benefits, scientists say - so where do hopes really lie?